ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±¹ù»ÀÁᣩ¿ËÈÕ£¬£¬ngµç×ÓÓÎÏ·Á¥ÊôµÚÒ»Ò½Ôº³¬Éùҽѧ¿ÆÐ»ÏþÑà½ÌÊÚÍŶÓÓëngµç×ÓÓÎÏ·ÖÊÁÏ¿ÆÑ§Ó빤³ÌѧԺ˧ÐÄÌνÌÊÚÍŶӵĽ»Ö¯Ñ§¿ÆÏàÖúÑо¿Ð§¹ûÔÚ¸ßÖÊÁ¿ÔÓÖ¾Nano TodayÉÏÒÔresearch articleµÄÐÎʽ½ÒÏþ¡£ ¸ÃÑо¿ÎªÒÔPD-1/PD-L1Ϊ°ÐµãµÄRFAºóÖ×Áö×ÛºÏÖÎÁÆÌṩÁËÀíÂÛÒÀ¾Ý£¬£¬ÎªÊÜÀ§ÓÚÃâÒßÒ©ÎïÄÍÒ©ºÍ¶¾¸±×÷ÓõÄÖ×Áö»¼Õß´øÀ´ÁËеÄÏ£Íû£¬£¬¶Ô¸ÄÉÆÖ×ÁöRFAÊõºóÔ¤ºó¾ßÓÐDZÔÚµÄÁÙ´²¼ÛÖµ¡£
É䯵ÏûÈÚ£¨Radiofrequency ablation, RFA£©ÒòÆä΢´´¡¢¡¢ÁÆÐ§È·ÇС¢¡¢×¡ÔºÊ±¼ä¶ÌµÈÓÅÊÆ£¬£¬ÒÑ¿ªÕ¹ÎªÖ×Áö×ÛºÏÖÎÁƵÄÖ÷Òª×é³É²¿·Ö£¬£¬ÆÕ±éÓ¦ÓÃÓÚÔ·¢»òÕß×ªÒÆÐÔ¸ÎÔàÖ×ÁöµÈʵÌåÖ×ÁöµÄÖÎÁÆ¡£¿ÉÊÇ£¬£¬¹ØÓÚÖ×ÁöÖ±¾¶´óÓÚ3 cm¡¢¡¢ÐÎ̬²»¹æÔò¡¢¡¢Î»ÓÚÖ÷ÒªÔàÆ÷¼°´óѪ¹ÜÅÔµÄÖ×Áö£¬£¬RFAÍùÍùÄÑÒÔµÖ´ïÍêÈ«ÏûÈÚ£¬£¬Êǵ¼ÖÂÖ×Áö¸´·¢Ï£ÍûµÄÖ÷ÒªÔÒò¡£ÓëÍâ¿ÆÊÖÊõÇгý²î±ðµÄÊÇ£¬£¬RFAÊÇͨ¹ýÈÈЧӦʹÖ×Áö±¬·¢ÔλÄý¹ÌÐÔ»µËÀ£¬£¬ÔÚÕâ¸öÀú³ÌÖУ¬£¬¿É´Ù·¢´ó×ÚÖ×ÁöÏà¹Ø¿¹ÔÊÍ·Å£¬£¬ÓÕµ¼»úÌ屬·¢¿¹Ö×ÁöÃâÒßЧӦ¡£È»¶ø£¬£¬Ð»ÏþÑà½ÌÊÚÍŶÓÔÚ¶àÄêÖ×ÁöÏûÈÚµÄÁÙ´²Êµ¼ù¼°Ïà¹ØÑо¿Öз¢Ã÷£¬£¬Ö×ÁöÏûÈÚÊõºóËù±¬·¢µÄ¿¹Ö×ÁöÃâÒßЧӦȱ·¦ÒÔÒÖÖÆÊ£ÓàÖ×Áö¸´·¢£¬£¬ÇÒ²¿·Ö»¼Õß·ºÆðÖ×Áö¶ñ»¯Ï£Íû£¬£¬ÏÖÔÚÏà¹Ø»úÖÆÉÐδÃ÷È·¡£
½üÄêÀ´£¬£¬³ÌÐòÐÔéæÃüÊÜÌå-1/³ÌÐòÐÔéæÃüÅäÌå-1£¨Programmed cell death protein-1/Programmed cell death ligand 1, PD-1/PD-L1£©Þ׿¹ÖÎÁÆÔÚÖ×ÁöÃâÒßÖÎÁÆÁìÓòÈ¡µÃÁËÖØ´óÍ»ÆÆ¡£Ð»ÏþÑà½ÌÊÚÍŶÓÔÚ²»ÍêÈ«ÏûÈÚÖ×Áö¶¯ÎïÄ£×ÓÖз¢Ã÷£¬£¬ÏûÈÚÊõºóÊ£ÓàÖ×ÁöÍâòPD-L1ÏÔÖøÉϵ÷£¬£¬ÕâÅú×¢PD-1/PD-L1¼ÓÈëÏûÈÚÊõºóÊ£ÓàÖ×Áö±¬·¢ÃâÒßÌÓÒÝ¡£È»¶ø£¬£¬»ØÊ×ÐÔÑо¿ºÍ¶¯ÎïʵÑéÊý¾Ý¾ùÅú×¢£¬£¬¼òµ¥PD-1/PD-L1Þ׿¹ÖÎÁƶÔRFAÊõºóÖ×ÁöÏ£ÍûÁÆÐ§Ç·¼Ñ¡£Ñо¿ÍŶӽøÒ»²½ÆÊÎö·¢Ã÷£¬£¬RFAÊõºóÊ£ÓàÖ×ÁöSTINGͨ·¼¤»îȱ·¦£¬£¬µ¼ÖÂÊ£ÓàÖ×ÁöÖÐTÁܰÍϸ°û½þÈóÉÙ£¬£¬ÊÇPD-1/PD-L1Þ׿¹ÖÎÁƲ»¼ÑµÄ¿ÉÄÜÔÒò¡£
¿ÉÊÇ£¬£¬ÏÖÔÚSTINGͨ·¼¤»î¼ÁºÍPD-1/PD-L1Þ׿¹¿¹ÌåÁªºÏÖÎÁÆÈÔ±£´æÄÑÌ⣺PD-1/PD-L1Þ׿¹¿¹ÌåºÍSTINGͨ·¼¤»îÒ©ÎïµÄÁÙ´²Ó¦ÓÃÈÔÊÜÏÞÓÚÒòÒ©Îï·Ç°ÐÏòÔËË͵¼ÖµÄÃâÒßÏà¹Ø¶¾¸±×÷ÓᣱðµÄ£¬£¬PD-L1¿¹Ìå¼°STING¼¤»î¼ÁµÄ×÷ÓÃλµã»®·ÖλÓÚÖ×Áöϸ°ûÍâò¼°¿¹ÔÌá³Êϸ°ûÄÚ£¬£¬ÐèÒªµÖ´ïÑÇϸ°û²ãÃæ¾«×¼µÝËͲſÉʵÏÖÒ©ÎïµÄÓÐÓÃÐͬ×÷Óá£
Ϊ½â¾öÕâÒ»ÄÑÌ⣬£¬¸ÃÑо¿½ÓÄÉ˧ÐÄÌνÌÊÚÍŶÓÑз¢µÄÉúÎïÏàÈÝÐÔµÄÁ×Ö¬ÖÊÁϼ°ÆäÍŶÓÖÆ±¸µÄÒ»ÖÖpHºÍMMP-2Ë«ÖØÃô¸ÐµÄÄÉÃ×ÄÒÅÝ£¬£¬ÊµÏÖÁËÑÇϸ°ûˮƽµÄ³ÌÐòÐÔ¾«×¼Ò©Îï¿ØÊÍ¡£ÄÉÃ×ÄÒÅݵÄˮǻ°ü¹üSTING¼¤»î¼Á£¬£¬±í²ãͨ¹ýMMP-2Ãô¸ÐµÄ¶ÌëÄPLGVRGżÁª¿¹PD-L1¿¹Ì塣ͬʱ£¬£¬Í¨¹ýËáÃô¸ÐµÄõ£°·¼üżÁªPEG£¬£¬¿É×è°¿¹PD-L1¿¹ÌåÓëPD-L1ÑôÐÔµÄÕý³£×éÖ¯Á¬Ïµ£¬£¬´Ó¶ø¸³ÓèÁËÄÉÃ×Ò©ÎïµÄÒþÉíÐÔÄÜ¡£µ±ÄÉÃ×Ò©Î︻¼¯ÔÚÖ×Áö×éÖ¯Öк󣬣¬PEG¿Ç²ãºÍ¿¹Ìå»®·ÖÔÚÊ£ÓàÖ×Áö΢ÇéÐεÄËáÐÔÌõ¼þºÍMMP-2µÄ´¥·¢ÏϹ½ÁÎÊÍ·Å¡£¶øPEGºÍ¿¹ÌåµÄÊÍ·ÅʹµÃÄÒÅݵÄÍâòµçλ´Ó¸ºµçÐԷתΪÕýµçÐÔ£¬£¬Ôö½øÁËÔØSTING¼¤»î¼ÁÄÒÅݱ»¿¹ÔÌá³Êϸ°ûÄÚÍÌ£¬£¬Ê¹µÃSTING¼¤»î¼ÁÔÚ°ûÖÊÓÐÓü¤»îSTINGͨ·¡£ÌåÍâºÍºÉÁöСÊóµÄʵÑéÊý¾Ý¾ùÅú×¢£¬£¬¸Ãϵͳ¿Éͨ¹ý¼¤»îÊ÷ͻ״ϸ°û£¬£¬ÔöÌí¿¹Ö×ÁöTÁܰÍϸ°ûµÄÁöÄÚ½þÈ󣬣¬´Ó¶øÏÔÖøÒÖÖÆRFAÊõºóÊ£ÓàÖ×ÁöµÄÏ£Íû¡£±ðµÄ£¬£¬Óë·ÇPEGÆÁÕϵÄÄÉÃ×Ò©Îï×éÏà±È£¬£¬PEGÆÁÕϲãÏÔÖø½µµÍÁËSTING¼¤»î¼ÁºÍ¿¹PD-L1¿¹ÌåÖÎÁƵ¼ÖµĸÎÔà¶¾ÐÔ¡£

MMP-2/pHË«Ãô¸ÐÖ¬ÖÊÌå¹²ÔØSTING¼¤»î¼ÁºÍ¿¹PD-L1¿¹ÌåÐͬ¼¤»îÉ䯵ÏûÈÚÊõºó¿¹Ö×ÁöÃâÒߣ¬£¬ÒÖÖÆÊ£ÓàÖ×ÁöÏ£ÍûºÍ¸´·¢
¸ÃÑо¿Êܵ½¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÖØ´óÑо¿ÍýÏëÏîÄ¿¡¢¡¢¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÃæÉÏÏîÄ¿¡¢¡¢¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÇàÄêÏîÄ¿¼°¹ãÖÝÊÐÖØµãÁìÓòÑз¢ÍýÏëÏîÄ¿µÈ×ÊÖú¡£ÂÛÎÄÎÊÌâΪ¡°Nanodrug shows spatiotemporally controlled release of anti-PD-L1 antibody and STING agonist to effectively inhibit tumor progression after radiofrequency ablation¡±¡£ngµç×ÓÓÎÏ·Á¥ÊôµÚһҽԺΪÂÛÎĵÚÒ»µ¥Î»¼°Í¨Ñ¶µ¥Î»£¬£¬Ð»ÏþÑà½ÌÊÚ¡¢¡¢Ë§ÐÄÌνÌÊÚ¡¢¡¢ÐìÃ÷¸±½ÌÊÚ¼°ÕÅ´ºÑô¸±Ñо¿Ô±ÎªÅäºÏͨѶ×÷Õߣ¬£¬ngµç×ÓÓÎÏ·Á¥ÊôµÚÒ»Ò½Ôº²©Ê¿ºó¹ù»ÀÁá¡¢¡¢ngµç×ÓÓÎÏ·Á¥ÊôµÚÆßÒ½ÔºÖúÀíÑо¿Ô±»Æ½ðÉú¼°ngµç×ÓÓÎÏ·Á¥ÊôµÚÒ»Ò½ÔºÖúÀíÑо¿Ô±Ì·ÑóΪÅäºÏµÚÒ»×÷Õß¡£
ÂÛÎÄÁ´½Ó£ºhttps://www.sciencedirect.com/science/article/pii/S1748013222000524